Journal:

Article Title: A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent

doi: 10.1128/AAC.46.5.1447-1454.2002

Figure Lengend Snippet: MICs of CMT-3 and AMB

Article Snippet: The MIC of CMT-3 was 2.0 μg/ml, and the 50% inhibitory concentration was about 1.0 μg/ml. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Organism Source a MIC (μg/ml) of: No. of strains CMT-3 AMB C. albicans ATCC 24433, ATCC 76615, ATCC 18804, ATCC 90028, CI 0.25->8 0.12-4.0 17 C. albidus ATCC 34140 2.0 1.0 1 C. glabrata CI 4.0-8.0 0.5-2.0 2 C. krusei ATCC 6258, CI 4.0->8.0 1.0-2.0 3 C. parapsilosis ATCC 22019, CI >8.0 1.0-2.0 2 C. tropicalis ATCC 750, CI 4.0->8.0 0.5-2.0 3 Absidia sp. CI 4.0 4.0 1 A. flavus CI 2.0 1.0 1 A. fumigatus ATCC 1022 2.0 2.0 1 Cunninghamella sp. CI 8.0 >8.0 1 E. floccosum CI 0.5 >8.0 1 Fonsecaea sp. CI 4.0 >8.0 1 M. canis CI 2.0 0.5 1 M. gypseum CI 1.0 4.0 1 P. boydii CI 0.25 >8.0 1 Penicillium sp. CI 0.5 0.25 1 P. variotii ATCC 22319 1.0 0.5 1 P. verrucosa CI 8.0 >8.0 1 Rhizopus sp. CI 1.0 0.5 1 S. apiospermum CI 0.5 >8.0 1 T. mentagrophytes CI 1.0 4.0 1 T. tonsurans CI 2.0 0.25 1 Tricothecium sp. CI 0.5 >8.0 1 T. rubrum ATCC 10218 0.5 1.0 1 Ulocladium sp. CI 1.0 2.0 1 Open in a separate window a CI, clinical isolate.

Techniques:

Journal:

Article Title: A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent

doi: 10.1128/AAC.46.5.1447-1454.2002

Figure Lengend Snippet: Inhibition of fungal viability by CMT-3 and AMB

Article Snippet: The MIC of CMT-3 was 2.0 μg/ml, and the 50% inhibitory concentration was about 1.0 μg/ml. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Organism Source a MIC (μg/ml) of: No. of strains CMT-3 AMB C. albicans ATCC 24433, ATCC 76615, ATCC 18804, ATCC 90028, CI 0.25->8 0.12-4.0 17 C. albidus ATCC 34140 2.0 1.0 1 C. glabrata CI 4.0-8.0 0.5-2.0 2 C. krusei ATCC 6258, CI 4.0->8.0 1.0-2.0 3 C. parapsilosis ATCC 22019, CI >8.0 1.0-2.0 2 C. tropicalis ATCC 750, CI 4.0->8.0 0.5-2.0 3 Absidia sp. CI 4.0 4.0 1 A. flavus CI 2.0 1.0 1 A. fumigatus ATCC 1022 2.0 2.0 1 Cunninghamella sp. CI 8.0 >8.0 1 E. floccosum CI 0.5 >8.0 1 Fonsecaea sp. CI 4.0 >8.0 1 M. canis CI 2.0 0.5 1 M. gypseum CI 1.0 4.0 1 P. boydii CI 0.25 >8.0 1 Penicillium sp. CI 0.5 0.25 1 P. variotii ATCC 22319 1.0 0.5 1 P. verrucosa CI 8.0 >8.0 1 Rhizopus sp. CI 1.0 0.5 1 S. apiospermum CI 0.5 >8.0 1 T. mentagrophytes CI 1.0 4.0 1 T. tonsurans CI 2.0 0.25 1 Tricothecium sp. CI 0.5 >8.0 1 T. rubrum ATCC 10218 0.5 1.0 1 Ulocladium sp. CI 1.0 2.0 1 Open in a separate window a CI, clinical isolate.

Techniques: Inhibition, Control

Journal: Journal of Biological Chemistry

Article Title: Phosphorylation of p50 NF-κB at a Single Serine Residue by DNA-dependent Protein Kinase Is Critical for VCAM-1 Expression upon TNF Treatment

doi: 10.1074/jbc.m110.158352

Figure Lengend Snippet: FIGURE 1. DNA-PK is required for VCAM-1 expression in response to TNF treatment. A, immunoblot analysis of extracts from untreated M059K (DNA- PK-proficient) or M059J (DNA-PK-deficient) cells with antibodies to human DNA-PKcs or GAPDH. B, M059K and M059J cells were stimulated with TNF for different times, after which protein extracts were subjected to immunoblot analysis with antibodies to VCAM-1 or GAPDH. Con, control. C, M059K and M059J cells were stimulated with 2 or 10 ng/ml IL-1 for 18 h, after which protein extracts were subjected to immunoblot analysis with antibodies to VCAM-1 or GAPDH. D and E, cells were treated with TNF for 6 h, after which total RNA was prepared and subjected to cDNA generation followed by conven- tional (D) or quantitative (E) PCR with primers specific to human VCAM-1 or -actin. *, different from respective untreated cells; #, different from TNF-treated M059K cells; p 0.01. F, M059K cells were treated with different doses of DNA-PKcs siRNA; 48 h later, protein extracts were prepared and subjected to im- munoblot analysis with antibodies to DNA-PKcs or GAPDH. G, M059K cells were treated with siRNA against DNA-PKcs or control siRNA; 48 h later, cells were treated with TNF for 18 h. Protein extracts were subjected to immunoblot analysis with antibodies to VCAM-1 or GAPDH. H, M059K cells were transduced with a lentiviral vector (Santa Cruz Biotechnology) expressing either control shRNA or an shRNA targeting DNA-PKcs. Forty-eight hours later, cells were treated with TNF for 18 h, and the resulting protein extracts were subjected to immunoblot analysis with antibodies to DNA-PKcs, VCAM-1, or GAPDH.

Article Snippet: H, M059K cells were transduced with a lentiviral vector (Santa Cruz Biotechnology) expressing either control shRNA or an shRNA targeting DNA-PKcs.

Techniques: Expressing, Western Blot, Control, Transduction, Plasmid Preparation, shRNA

Journal:

Article Title: Potato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3

doi: 10.1128/AAC.46.5.1455-1461.2002

Figure Lengend Snippet: Comparison of the MICs of fluconazole, ketoconazole, and CMT-3 determined by the BMM and the PDA method

Article Snippet: For these two azole drugs, the BMM/PDA method MIC ratios were between 0.25 and 1 (no more than a 2 log 2 dilution difference), values which represent an allowable shift in laboratory practice. table ft1 table-wrap mode="anchored" t5 TABLE 4. caption a7 Organism a and antifungal agent MIC (μg/ml) determined by: Difference b (log 2 dilutions) BMM PDA method C. parapsilosis (ATCC 22019) Fluconazole 2.0 4.0 +1 Ketoconazole 0.12 0.12 0 C. krusei (ATCC 6258) Fluconazole 32 32 0 Ketoconazole 0.5 1.0 +1 P. boydii (CI) Fluconazole 8 16 +1 Ketoconazole 1.0 2.0 +1 CMT-3 32 0.25 −7 C. glabrata (CI) Fluconazole 8 16 +1 Ketoconazole 4.0 4.0 0 CMT-3 32 4 −3 Y. lipolytica (CI) Fluconazole 2.0 4.0 +1 Ketoconazole 0.25 1.0 +2 CMT-3 32 2.0 −4 C. albicans (ATCC 24433) Fluconazole 4.0 4.0 0 CMT-3 16 0.5 −5 P. variotii (ATCC 22319) Ketoconazole 0.12 0.25 +1 CMT-3 16 1.0 −4 A. fumigatus (ATCC 1022) Ketoconazole 4.0 4.0 0 CMT-3 >64 2.0 <−5 Penicillium sp. (CI) Ketoconazole 1.0 2.0 +1 CMT-3 16 0.5 −5 Rhizopus sp. (CI) Ketoconazole 1.0 4.0 +2 CMT-3 32 1.0 −5 A. flavus (CI), CMT-3 64 2.0 −5 Open in a separate window a CI, clinical isolate. b Difference between PDA method result and BMM result.

Techniques: Comparison